For instance, in a study investigating anti-FOLR1 (folate receptor-1) and anti-CEA (carcinoembryonic antigen) therapy, under the presence of PBMC, signs of on-target off-tumor toxicity were observed, as evidenced by elevated levels of IFN-γ, granzyme B, and IL-6 by PBMC, by anti-FOLR1 engager against healthy lung and kidney cells, and by anti-CEA antibody against healthy duodenum cells in the chip [131]. This evidence concerns the gene FOLR1 and neoplasm.